Trial of a Gastrin Receptor Antagonist in Barrett's Esophagus

Phase 2 Completed 27 enrolled Columbia University Trio Medicines Ltd. · collab

RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this study is to determine whether treatment with an experimental drug called YF476 in patients with Barrett's esophagus reduces the expression of tissue markers that are associated with an increased risk of developing esophageal cancer.

Timeline

Start: 2010-06
Primary completion: 2017-12
Completion: 2017-12

Outcome

Missed primary endpoint

paper There was no difference between arms in mean change in cellular proliferation PMID 33782049 ↗

paper The gastrin/CCK2 receptor antagonist netazepide did not reduce cellular proliferation in patients with nondysplastic Barrett's esophagus. PMID 33782049 ↗

Publications

Results Abrams JA, Del Portillo A, Hills C, Compres G, Friedman RA, Cheng B, Poneros J, Lightdale CJ, De La Rue R, di Pietro M, Fitzgerald RC, Sepulveda A, Wang TC. Randomized Controlled Trial of the Gastrin/CCK2 Receptor Antagonist Netazepide in Patients with Barrett's Esophagus. Cancer Prev Res (Phila). 2021 Jun;14(6):675-682. doi: 10.1158/1940-6207.CAPR-21-0050. Epub 2021 Mar 29.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	netazepide	Protein / enzyme biologic	25 mg	Oral